ClinicalTrials.Veeva

Menu

Structured Light Plethysmography Against Standard of Care in the Diagnosis and Monitoring of Dysfunctional Breathing (SLPDB)

P

PneumaCare

Status

Begins enrollment in 5 months

Conditions

Dysfunctional Breathing

Treatments

Device: Thora3DiTM

Study type

Observational

Funder types

Industry

Identifiers

NCT04255446
PCL-SLPDB-2020

Details and patient eligibility

About

This is an observational, controlled, single-centre study to validate the Thora3Di™ against standard practice in patients who are undergoing investigation for disproportionate breathlessness. The core methodology involves capturing of data during a short period of measurement of breathing using SLP.

Full description

Cohort A: This study is a pilot study with four study visits (Screening, Baseline, week 13 and week 26) to generate data to characterise the tidal breathing patterns and parameters with Thora3Di™. Subjects will have a screening visit within 0 to 14 days prior to the first study visit. For each study visit, subjects will be seen in the clinical research facility and have two 5-minute SLP measurements (at rest and on exertion). The SLP measurement should be performed prior to standard lung function tests with minimal impact on clinical time and not change to hospital attendance. Also, each visit subjects will be asked to report concomitant medications and adverse events, and fill several questionnaires forms as outlined in the SOAs.

Cohort B: Healthy subjects will have only one visit for this study. After signing the informed consent form, subjects will undergo two 5-minutes SLP measurements (at rest and on exertion).

Enrollment

60 estimated patients

Sex

All

Ages

16 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • • Cohort A: Any adult who is presenting with controlled disproportionate breathlessness will be considered for inclusion as a diseased subject (with excluded comorbidities as cause of breathlessness e.g. uncontrolled asthma (GINA 2019 guidelines), uncontrolled cardiac disease, ILO).

    • Cohort B: Any adult who is in good respiratory health will be considered for inclusion as a normal in the study.

Exclusion criteria

  • Subject unable to sit in an upright position for required period

    • Subjects with significant co morbidities (assessed by the clinician at screening only):
    • Chest wall or spinal deformity e.g. scoliosis OSA, Apnoea hypopnoea index > 30 (if known)
    • Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participants' ability to participate in the study
    • BMI > 40
    • Height > 194 cm
    • Female participant who is pregnant, lactating or planning pregnancy during the course of the study
    • Inability to consent/comply with trial protocol

Trial design

60 participants in 2 patient groups

Dysfunctional Breathing
Description:
Patients with Dysfunctional breathing age between 16 to 75 will be included.
Treatment:
Device: Thora3DiTM
Healthy Volunteers
Description:
Healthy Volunteers without any respiratory problems age between 16 to 75 will be included.
Treatment:
Device: Thora3DiTM

Trial contacts and locations

1

Loading...

Central trial contact

Gin Lee; Jenny Harrison

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems